Navigation Links
This is a Letter From Nicusa Capital Urging BioClinica Shareholders to Vote AGAINST Proxy Proposal 2 and WITHHOLD Votes From Incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy
Date:5/4/2011

NEW YORK, May 4, 2011 /PRNewswire/ -- This is a letter from Nicusa Capital urging BioClinica (Nasdaq: BIOC) shareholders to vote AGAINST Proxy Proposal 2 and WITHHOLD votes from incumbent Directors Berg, Olukotun, Parker and Weinstein on 2011 Proxy:

May 4, 2011

Dr. David E. Nowicki
Chairman of the Board
BioClinica, Inc.
826 Newtown-Yardley Rd.
Newtown, PA  18940

Dear Dr. Nowicki and the Board of Directors of BioClinica:

As of May 4, 2011, Nicusa owns 854,119 shares, or approximately 5.5%, of the outstanding shares of BioClinica.  We have been a shareholder since May 2007 and have been on file as a 5% holder since July 2007.  

In September 2010 we wrote a letter to the Board outlining our concerns as a long-term shareholder, and gave a detailed presentation to the Board on November 17 in an attempt to constructively address the shortcomings in corporate governance at BioClinica.  We are more than willing to share our analysis and supporting materials with other concerned shareholders.

Unfortunately, after reviewing BioClinica's 2011 Proxy, the Board has not addressed our concerns sufficiently.  As a result, we will vote against, and ask other shareholders to vote against, Proposal 2 on the Proxy.  We will also withhold our vote, and ask other shareholders to do the same, from incumbent Directors Berg, Olukotun, Parker and Weinstein.

Our issues with the Company's corporate governance primarily lie in two areas: the Shareholder Rights Agreement, which we will refer to as the "Poison Pill," and management compensation.

Poison Pill

Our Company does not need a poison pill.  The Board imposed the Poison Pill on shareholders without input, and has yet to provide a convincing justification for keeping it.  Absent a compelling, public, specific and timely argume
'/>"/>

SOURCE Nicusa Capital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc.
2. Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc.
3. EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
6. BioProcess International Launches Monthly Asia-Pacific eNewsletter
7. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
8. U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
9. BioSoteria Drug Safety Newsletter Reaches Milestone
10. Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
11. Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... GeneMorph PCR mutagenesis kit produces a unique , mutational spectrum , ... , , ... Stratagene , , , ... The , GeneMorph PCR , mutagenesis kit ...
... cDNA gene clusters are novel and more ,than 50% ... Goncalves Jean-Michel Lelias Joe Sorge ,Stratagene , ... ,goes beyond normal cDNA collections. Stratagene has searched ... of cDNAs that are not found ,in the UniGene ...
... need to manually pour gels, saving up,to 4 hours ... to bubbles or leaking.All CastAway gels are guaranteed to ... date of manufacture, with no,detectable deterioration in band resolution. ... Stratagene adds a new 6% gel to the growing ...
Cached Biology Technology:Randomize Gene Sequences with New PCR Mutagenesis Kit 2Randomize Gene Sequences with New PCR Mutagenesis Kit 3Randomize Gene Sequences with New PCR Mutagenesis Kit 4Randomize Gene Sequences with New PCR Mutagenesis Kit 5Randomize Gene Sequences with New PCR Mutagenesis Kit 6Randomize Gene Sequences with New PCR Mutagenesis Kit 7Randomize Gene Sequences with New PCR Mutagenesis Kit 8Randomize Gene Sequences with New PCR Mutagenesis Kit 9Randomize Gene Sequences with New PCR Mutagenesis Kit 10Randomize Gene Sequences with New PCR Mutagenesis Kit 11The GeneZoo or the GeneJungle? 2The GeneZoo or the GeneJungle? 3The GeneZoo or the GeneJungle? 4The GeneZoo or the GeneJungle? 5The GeneZoo or the GeneJungle? 6The GeneZoo or the GeneJungle? 7The GeneZoo or the GeneJungle? 8The GeneZoo or the GeneJungle? 9The GeneZoo or the GeneJungle? 10Four New CastAway Precast Gels 2
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... rapidly and to an unexpected extent. The outbreak does ... the virus shows a new disease dynamic in regions, ... reason, the German National Academy of Sciences Leopoldina, acatech ... the Union of the German Academies of Sciences and ... today. , In the statement the academies call for ...
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... , AMIA, the association for professionals in biomedical and ... the National Coordinator on Health Information Technology (DHHS/ ONCHIT), ... meaningful use of electronic health records (EHRs) over the ... Policy Committee (HITPC), on the continuation of support for ...
... When patients receive a bone marrow transplant, they are getting ... are needed when a patient is low on red blood ... be caused by cancer or even cancer treatments such as ... transplant might not succeed because the transplanted stem cells don,t ...
... Spanish . Fernando Rendo, biologist at the ... with the intention of completing the genealogical tree ... Country Autonomous Community (CAPVEAE) and Navarre. Concretely, he opted for ... (a kind of variation in the DNA sequence) that can ...
Cached Biology News:AMIA on meaningful use: Invest in people and technology 2How long do stem cells live? 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 2Basque thesis investigates wide diversity within certain ovine, bovine and equine breeds 3
... Genomic Labeling Systems are a high-performance labeling ... DNA samples for array-based Comparative Genomic Hybridization ... labeling formats, the BioPrime Plus Array CGH ... to your genomic labeling needs. Using ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
...
Biology Products: